Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade.
Ontology highlight
ABSTRACT: The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients poses significant challenges. To date, analyses of tumor biopsies are the only parameter used to guide prognosis to ICI therapy. Tumor biopsies, however, are often difficult to obtain and tissue-based biomarkers are limited by intratumoral heterogeneity and temporal variability. In response, there has been a growing emphasis on the development of "liquid biopsy"‒ derived biomarkers, which offer a minimally invasive means to dynamically monitor the immune status of NSCLC patients either before and/or during the course of treatment. Here we review studies in which multiple blood-based
SUBMITTER: Tsai YT
PROVIDER: S-EPMC10944611 | biostudies-literature | 2024 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA